ssDNA Aptamers Targeting P97 Protein for Mycoplasma Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for M. hyopneumoniae infection in swine are inadequate, as existing antibiotics and vaccines do not completely eliminate the infection and provide variable results due to factors like improper storage, antigenic differences, and interference from other diseases, leading to ongoing disease severity and transmission.
Innovation Solution
Development of ssDNA aptamers specifically binding to the P97 surface protein of M. hyopneumoniae using the SELEX method, which can be used for detection and treatment by inhibiting the bacterium's adherence to host cells, and subsequent modification for rapid detection on biosensor surfaces.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotics are used to treat M. hyopneumoniae infection, then bacterial growth is inhibited, but the infection is not completely eliminated and variable results occur due to storage conditions, antigenic differences, and interference from other diseases
Solution Approach 1:
The patent replaces traditional antibiotic-based chemical treatment with a biosensor system that uses biological recognition elements (aptamers or antibodies) to detect M. hyopneumoniae. This substitution provides more reliable and consistent detection results that are not affected by antibiotic resistance, storage conditions, or antigenic variations, as the biosensor directly detects bacterial presence through specific molecular binding.
Solution Approach 2:
The patent introduces biosensors as intermediary detection tools that bridge the gap between M. hyopneumoniae presence and diagnostic information. These biosensors use specific binding molecules (aptamers or antibodies) as mediators to recognize and bind to target antigens on the bacteria, providing accurate detection without the variability associated with antibiotic treatment responses.
2Reliability
If vaccines are used to prevent M. hyopneumoniae infection, then morbidity and mortality are reduced, but the disease severity and transmission are not completely prevented due to antigenic differences between field strains and vaccine strains
Solution Approach 1:
The patent replaces vaccine-based preventive approaches with biosensor-based detection systems. Instead of relying on antigenic matching between vaccines and field strains, the biosensor directly detects the presence of M. hyopneumoniae through specific binding to conserved bacterial antigens, providing accurate identification regardless of strain variation or prior vaccination status.
3Duration of action of moving object
If pulse medication and strategic medication programs are implemented to prolong medicinal protection, then treatment duration is extended, but complete elimination of M. hyopneumoniae and development of herd immunity are not achieved
Solution Approach 1:
The patent replaces extended antibiotic treatment programs with rapid biosensor detection systems. By enabling early and accurate detection of M. hyopneumoniae presence, the biosensor allows for targeted intervention strategies that can completely eliminate infections before they establish persistent colonies, avoiding the need for prolonged medication that fails to achieve complete eradication.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The aptamers effectively prevent M. hyopneumoniae binding to cilia, offering a more reliable diagnostic and therapeutic approach, potentially reducing disease severity and transmission by targeting specific adhesins involved in infection.
Implementation Method 1
ssDNA aptamers specifically binding to the P97 surface protein of M. hyopneumoniae
Data Source
AI summary
The present disclosure relates to aptamers, polynucleotides, and nuclei acid molecules, which include a polynucleotide sequence capable of specifically binding polypeptides participating in M. hyopneumoniae infection. Also provided are methods of using nucleic acid molecules, polynucleotides and synthetic antibodies directed there against for detection, treating and neutralization of M. hyopneumoniae infection.